Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

1362602

USP

Levonorgestrel

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

D(−)-Norgestrel, 13β-Ethyl-17α-ethinyl-17β-hydroxygon-4-en-3-on, 17α-Ethinyl-18-homo-19-nortestosteron, 18,19-Dinor-13β-ethyl-17β-hydroxy-4-pregnen-20-in-3-on, 18,19-Dinor-4-pregnen-20-in-3-on, Levonorgestrel

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H28O2
CAS-Nummer:
797-63-7
Molekulargewicht:
312.45
MDL-Nummer:
MFCD00199013
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750050
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

levonorgestrel

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C

InChI

1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1

InChIKey

WWYNJERNGUHSAO-XUDSTZEESA-N

Angaben zum Gen

human ... PGR(5241)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Levonorgestrel USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Health hazard
GHS08

Signalwort

Danger

Gefahreneinstufungen

Carc. 2 - Lact. - Repr. 1A

Lagerklassenschlüssel

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 5

1 of 5

Ethinylestradiol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1480

Ethinylestradiol

Norethindron United States Pharmacopeia (USP) Reference Standard

USP

1469005

Norethindron

Ethinylestradiol European Pharmacopoeia (EP) Reference Standard

E1900000

Ethinylestradiol

Sigma-Aldrich

Sigma-Aldrich

89904

Mikropartikel auf Polystyrolbasis

17α-Ethinylestradiol ≥98%

Sigma-Aldrich

E4876

17α-Ethinylestradiol

Y-L Wan et al.
Climacteric : the journal of the International Menopause Society, 14(6), 622-632 (2011-10-25)
Oral progestogens are commonly used for endometrial protection in women at higher risk of developing endometrial abnormality. Long-term intrauterine progestogens may offer an attractive alternative to oral therapy. To review the evidence regarding the efficacy of intrauterine levonorgestrel-releasing systems (LNG-IUS)
Richard F Lowe et al.
Contraception, 87(4), 486-496 (2012-11-06)
The use of intrauterine devices as a contraceptive method has been steadily growing in developing countries. Anemia in reproductive-age women is a growing concern in those settings. A systematic review of studies with measured hemoglobin and serum ferritin at baseline
Paul D Blumenthal et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 112(3), 171-178 (2011-01-29)
To review the literature for economic and health-related quality of life outcomes data associated with the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of heavy menstrual bleeding. We searched the MEDLINE and EMBASE databases simultaneously using the
Ayman A A Ewies et al.
Obstetrical & gynecological survey, 67(11), 726-733 (2012-11-16)
Endometrial hyperplasia is a commonly seen gynecological condition that affects women of all age groups. Whereas hysterectomy is the most preferred treatment option for complex endometrial hyperplasia with atypia, there is no consensus regarding the first-line management of women with
Lisa L Bayer et al.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 52(4 Suppl), S54-S58 (2013-04-03)
The levonorgestrel intrauterine system (LNG-IUS) is an underused contraceptive method in adolescent populations. In addition to being a highly effective, reversible, long-acting contraception, the LNG-IUS has many noncontraceptive health benefits including reduced menstrual bleeding, decreased dysmenorrhea and pelvic pain related
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.